Status: Enrolling
Investigator: Jenny Chang
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative br ... Read more >
Status: Enrolling
Investigator: Warren Ellsworth
Study Coordinator:
Phone:
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Enrolling
Investigator: Aldona Spiegel
Study Coordinator:
Phone:
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Open Not Enrolling
Investigator: Ivo Tremont-Lukats
Study Coordinator:
Phone:
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblatoma (GBM) or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 3 cohorts, Cohorts A, B, and ... Read more >
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >
Status: Enrolling
Investigator: Dharamvir Jain
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. ... Read more >
Status: Open Not Enrolling
Investigator: Anaum Maqsood
Study Coordinator: Tanya Khan
Phone: 346.238.5655
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >
Status: Open Not Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator:
Phone:
This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >
Status: Open Not Enrolling
Investigator: Sandra Templeton
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes th ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a dru ... Read more >
Status: Open Not Enrolling
Investigator: Dharamvir Jain
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemothera ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator:
Phone:
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has co ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Mary Rose Silvas
Phone: 713.441.1952
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >
Status: Enrolling
Investigator: Dharamvir Jain
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III hist ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is comp ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Miguel Valdivia y Alvarado
Phone: 346.238.2626
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoemboli ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alon ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator:
Phone:
The purpose of this exploratory biomarker study is to further our understanding of the role of cancer stem cells (CSCs) and other biomarkers in the progression of COPD to lung cancer by examining the CSC population and other related biomarkers, ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: ? ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >
Status: Enrolling
Investigator: Jenny Chang
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective. ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5268
The purpose of this exploratory biomarker study is to further our understanding of the role of CSCs in lung cancer metastasis by examining the CSC population in metastatic tissue. ... Read more >
Status: Enrolling
Investigator: Tarrik Zaid
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. ... Read more >
Status: Enrolling
Investigator: Jenny Chang
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this c ... Read more >
Status: Enrolling
Investigator: Jenny Chang
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >
Status: Enrolling
Investigator: Nestor Esnaola
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metasta ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator:
Phone:
We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcome ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >
Status: Open Not Enrolling
Investigator: David Baskin
Study Coordinator: Helga Jones
Phone: 713.363.9388
" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Grbavac
Phone: 346.238.4456
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >
Status: Open Not Enrolling
Investigator: Dharamvir Jain
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator:
Phone:
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense ho ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no mo ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Tanya Khan
Phone: 346.238.5655
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cance ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator:
Phone:
NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator:
Phone:
NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator: Gabrielle Hayes
Phone: 734.419.948
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >
Status: Enrolling
Investigator: Nestor Esnaola
Study Coordinator: Derek Cole
Phone: 713.441.5607
This is a prospective study that will recruit male and female study participants, ages 55 to 80, already enrolled in Lung Cancer Screening program at all Houston Methodist Hospital locations. The goal of this study is to develop powerful inte ... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >
Status: Enrolling
Investigator: Jenny Chang
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with a ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >
Status: Open Not Enrolling
Investigator: Kirk Heyne
Study Coordinator: Tanya Khan
Phone: 346.238.5655
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >
Status: Open Not Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Taliah Muhammad
Phone: 346.238.4523
Primary Purpose: Treatment ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 832.406.0291
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >